Physician Sentiment on PADCEV®

Q: What do oncologists think of the EV-302 trial (PADCEV®)?

Across 27 verified physician voices in KOL Pulse's index for EV-302, 22% expressed positive sentiment, 11% were nuanced (praising the result while flagging a caveat), 67% were neutral, and 0% were critical. Positive voices highlight the first regimen to beat platinum-based chemotherapy in advanced urothelial cancer, establishing enfortumab vedotin + pembrolizumab as the new first-line standard of care; nuanced and critical voices flag cumulative toxicity of the ADC + immunotherapy backbone (including skin and neuropathy) and patient selection/sequencing in real-world practice.

Q: Where can I find the EV-302 trial data for PADCEV® (enfortumab vedotin)?

EV-302 is registered as NCT04223856 and studied PADCEV® (enfortumab vedotin) in 1L locally advanced or metastatic urothelial cancer (EV + pembrolizumab). For the full EV-302 trial data and conference coverage, see the KOL Pulse EV-302 trial profile at kolpulse.com/kol-pulse-trial-profile-ev302.

Q: What do oncologists think of the KEYNOTE-B15 / EV-304 trial (PADCEV®)?

Across 43 verified physician voices in KOL Pulse's index for KEYNOTE-B15 / EV-304, 30% expressed positive sentiment, 7% were nuanced (praising the result while flagging a caveat), 63% were neutral, and 0% were critical. Positive voices highlight the first platinum-free perioperative regimen to improve outcomes over standard chemotherapy in muscle-invasive bladder cancer, moving enfortumab vedotin + pembrolizumab into curative-intent therapy; nuanced and critical voices flag a shrinking candidate population versus competing approaches (e.g. ctDNA-guided adjuvant immunotherapy), perioperative toxicity, and overall-survival maturity.

Q: Where can I find the KEYNOTE-B15 / EV-304 trial data for PADCEV® (enfortumab vedotin)?

KEYNOTE-B15 / EV-304 is registered as NCT04700124 and studied PADCEV® (enfortumab vedotin) in Perioperative (neoadjuvant + adjuvant) muscle-invasive bladder cancer undergoing radical cystectomy (EV + pembrolizumab). For the full KEYNOTE-B15 / EV-304 trial data and conference coverage, see the KOL Pulse KEYNOTE-B15 / EV-304 trial profile at kolpulse.com/kol-pulse-trial-profile-keynote-b15.

Q: Is PADCEV® (enfortumab vedotin) FDA approved?

PADCEV® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-13. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT04223856

What do oncologists think of the EV-302 trial (PADCEV®)?

EV-302 — 1L locally advanced or metastatic urothelial cancer (EV + pembrolizumab)

FDA APPROVED · Dec 2023FDA-approved (full approval) December 15, 2023, in combination with pembrolizumab for adult patients with locally advanced or metastatic urothelial cancer.

Physicians are broadly favorable, with real nuance on EV-302: 22% of 27 verified physician voices positive, 11% nuanced (praising the result while flagging a caveat), 67% neutral, 0% critical.

22%

11%

67%

Positive 22% Nuanced 11% Neutral 67% Critical 0%

Denominator: 27 distinct verified physician voices across 67 oncologist posts, 2024-01-27 to 2026-05-30. Sponsor: Astellas Pharma (with Pfizer/Seagen and Merck)

See full EV-302 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04223856 · FDA — EV-302 first-line approval (Dec 2023)

FDA approval (Dec 15, 2023): enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer (based on EV-302 / KEYNOTE-A39, NCT04223856).

Physician voices — verbatim

Representative positive voice

Congrats @shilpaonc for oral ab#4502 @ASCO #ASCO25👉https://t.co/dtFXREYI6n👉In the Ph3 EV-302 trial in mUC #bladdercancer, pts achieving a CR had higher PFS & OS w/ EV+P vs. chemo (exploratory analysis)👇@umangtalking @OncoAlert @urotoday @Uromigos @BladderCancerUS @tompowles1

Neeraj Agarwal, MD, FASCO

@neerajaiims

Representative nuanced voice

#GU24 #bladdercancer highlights in my opinion: 1) AMBASSADOR Phase III @apolo_andrea-improved DFS for adjuvant pembro x 1 year vs. observation in high-risk muscle-invasive #urothelialcarcinoma (HR 0.69, median 29 v 14 mo, OS immature), 2) EV302 Phase III @MichvdHeijden: improved… https://t.co/G5iZ5Oq7zp

Guru P. Sonpavde, MD

@sonpavde

Full physician voice list (27)

Physician	Comment (verbatim)	Sentiment	Impressions
Oncology Brothers @OncBrothers	Day 1 #ASCO26 highlights: 1. #CROWN (update): ALK+ NSCLC 2. #OptiTROPLung05: SacTMT/IO NSCLC 3. #WuKONG28: EGFR 20 NSCLC 4. #EV302 (update): EV-Pembro mUC 5. #MajesTEC9: Teclistamab in RRMM 6. #SUCCESSOR2: Mezigdomide in RRMM #…	Neutral	15,989
Neeraj Agarwal, MD, FASCO @neerajaiims	Congrats @shilpaonc for oral ab#4502 @ASCO #ASCO25👉https://t.co/dtFXREYI6n👉In the Ph3 EV-302 trial in mUC #bladdercancer, pts achieving a CR had higher PFS & OS w/ EV+P vs. chemo (exploratory analysis)👇@umangtalking @OncoAlert @urotoday @Ur…	Positive	15,234
Tom Powles @tompowles1	Enfortumab Vedotin + pembro shows broad spectrum of activity for RR PFS and OS in all subgroups. This includes subsets such as lymph node disease, liver mets, PD-L1 status, upper tract disease, platinum eligibility. This +ve data underlines…	Positive	7,221
Karine Tawagi MD @DrKarineTawagi	GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC…	Neutral	6,216
Toni Choueiri, MD @DrChoueiri	Terrific work by @tompowles1 !! With >2 years of follow-up, 1L EV+P maintains superior OS and PFS vs chemo in la/mUC. cCR rate doubled (30.4% vs 14.5%), with longer response durability and no new safety signals. EV+P remains SOC! @QMBCI @s…	Positive	6,116
Dra. María Natalia Gandur Quiroga @nataliagandur	🌟📢 @ASCO #GU25 \| Abstract #664 🔬 EV-302 confirms superior efficacy of EV+P vs chemo in 1L la/mUC!🌟 @tompowles1 @shilpaonc 📊 Key Findings (N=886, Median FU: 29.1 months) ✅ Median OS: 33.8 vs. 15.9 months (HR: 0.51, 95% CI: 0.43-0.61) ✅ PFS …	Neutral	4,986
Guru P. Sonpavde, MD @sonpavde	#GU24 #bladdercancer highlights in my opinion: 1) AMBASSADOR Phase III @apolo_andrea-improved DFS for adjuvant pembro x 1 year vs. observation in high-risk muscle-invasive #urothelialcarcinoma (HR 0.69, median 29 v 14 mo, OS immature), 2) E…	Nuanced	4,659
Shilpa Gupta @shilpaonc	#GU25 @ASCO @tompowles1 presents the spectacular data from EV302 with median fu of 2.5 years. EV-pembrolizumab continues to show maintenance of significantly improved OS & PFS compared to platinum. DoR ~ 2 yrs & in pts with confirmed CR, …	Neutral	4,531
Enrique Grande @drenriquegrande	At @asco #GU25 we will see the 29.1 months median follow-up updated data from EV302!!!! 30.4% of pts in the EV+P arm achieved cCR!! Median duration of cCR was not reached for EV+P vs 15.2 mo (95% CI, 10.3-NE) for chemo. Definitely there’s …	Neutral	4,459
Yüksel Ürün @DrYukselUrun	#GU24 @ASCO Urothelial highlights: ⏺️AMBASSADOR @apolo_andrea This trial focused on adjuvant pembrolizumab for patients with high-risk muscle-invasive urothelial carcinoma. The results showed improved disease-free survival (DFS) for patie…	Neutral	4,370
Dr Rishabh Jain @DrRishabhOnco	#ASCO26 EV + pembrolizumab is not just holding the line in 1L metastatic urothelial cancer. It is deepening responses over time. EV-302 / KEYNOTE-A39 3.5-year update ⚡ Median OS 33.6 vs 15.9 months HR 0.53 ⚡ 42-month OS 44.0% vs 24.6% …	Neutral	3,748
Michael Serzan, MD @MikeSerzanMD	🗣️Bladder Cancer Rapid Oral Abstracts #GU25 Dr @tompowles1 Abs664: Updates Analysis of #EV302 N = 886 Median Follow up 29.1 mo EV+P vs Chemo ✅ PFS (HR, 0.48, 0.41-0.57) ✅ OS (HR, 0.51, 0.43-0.61) ✅ ORR 67.5% vs 44.2% ✅ DOR 23.3mo vs…	Neutral	3,576
Tian Zhang, MD, MHS @TiansterZhang	with subgroup analysis of #EV302 — benefit across subgroups, not surprising given the initially reported results. Our patients @utswcancer have benefited from combo EV-pembro! #GU24 @ASCO @OncoAlert	Positive	1,575
David J. Benjamin, MD @DavidBenjaminMD	Is the field of genitourinary oncology pivoting away from precision medicine -- and towards imprecision? In @BJUIjournal, @ArashRezazadeh6 and I cite two recent examples of TALAPRO-2 (for metastatic hormone resistant prostate cancer) and E…	Neutral	1,495
Dr Amol Akhade @SuyogCancer	📢 New EV-302 results @ASCO25 Exploratory analysis of pts with complete response (cCR) in 1L la/mUC: ❤️‍🔥 EV+P vs Chemo (cCR group): ✔️ cCR rate: 30.4% vs 14.5% ✔️ 24-mo PFS: 78.2% vs 53.7% ✔️ Median PFS: Not reached vs 26.9 mo ✔️ 24-mo OS: …	Positive	1,386
Katy Beckermann @katy_beckermann	EV+pembro is now first-line standard after EV-302 (updated at #ASCO26). 6 urothelial trials at ASCO 2026 are already testing what follows, 3 in Phase 3. 📈 Two TROP-2 strategies: Dato-DXd post-EV/pembro (TROPION-Uro03) + SG+pembro in ICI-re…	Neutral	1,337
Tuğba Başoğlu, MD @tugbawitter	One of the most important messages from the EV-302 update: Responses continue to deepen over time. Nearly 30% of patients achieved CR, and ~90% of those complete responders remain alive at 3.5 years. #ASCO2026 @Larvol @OncoAlert @ozdogan…	Neutral	981
Mario Balsa @MarioBalsaMD	🚨 EV-302: enfortumab vedotin + pembrolizumab vs platinum chemotherapy in 1L metastatic urothelial carcinoma (phase III, n=886) #ASCO26 🎯 Median OS: 33.6 vs 15.9 months (HR 0.53) \|\| 3.5-year OS: 44.0% vs 24.6% 💥 CR rate doubled: 30.4% vs 14…	Positive	862
Carlos Alvarez @duemed	Discussion of PemCab and subgroup analyses of EV-302 @Parminder1699 #GU24	Neutral	667
Carissa Chu @CChuMD	delivers a tour de force presentation @AACR on resistance mechanisms to NECTIN4 therapy (enfortumab and CAR-T) in bladder cancer. @UCSFCancer #AACR26 The takeaways:	Neutral	583
Byung-June Park @onco_park	#ASCO24 #UrothelialCarcinoma Topic 2: EV-302 demonstrated superior survival benefits compared to platinum-based chemotherapy in both cis-ineligible and eligible patients. So, what treatments can we offer patients treated with enfortumab ve…	Neutral	421
Mustafa Özdoğan, MD @ozdogan_md	ASCO 2026 \| Abstract 4507 With 3.5 years of follow-up, the EV-302 trial confirms that enfortumab vedotin plus pembrolizumab maintains a significant and durable overall survival benefit over platinum-based chemotherapy in first-line advance…	Neutral	349
Rashid K. Sayyid @RKSayyid	EV-302 extended 3.5-yr FU data: 1L EV+P vs chemo in la/mUC (n=886) 🔹OS: 33.6 vs 15.9 mo (HR 0.53) 🔹ORR: 68% vs 44%; CR: 30% vs 15% 🔹Of pts achieving CR with EV+P, 20% converted from PR→CR 🔹Median time to CR: 4.3 mo overall; 6.6 mo for PR→C…	Neutral	312
Jun Gong @jgong15	EV-302 of #1L EV-P vs platinum-chemo in #mUC ➡️ updated OS at 3.5 yrs 44% vs 24.6% alive, median 4.3 mos to #CR w/even pts up to 1 yr converting from #PR to #CR, 10% achieve #CR at first scan w/EV-P, (median duration of EV 7.1 mos & 8.5 mos…	Neutral	198
Anita Turk @anita_turk	Dr Jennifer King with bladder cancer updates: NIAGARA shows perioperative durvalumab improves EFS regardless of pCR/ctDNA status. EV-302 demonstrates 50% maintained response at 24 months among responders. TROPiCS-04 confirms no OS differenc…	Nuanced	159
Dillon Cockrell, MD @DCockrellMD	Response rates for gem/cis/nivo were not as impressive as EV/pembro in EV-302, however given possible toxicity experienced with EV (particularly neuropathy, rashes, hyperglycemia, ocular) this may still be a good option for certain patients…	Nuanced	83
Maroun Bou Zerdan, MD @MarounBouZerdan	With 2.5 yrs median FU, EV-Pembro maintains significantly improved OS & PFS vs. platinum. DoR ~2 yrs, and in confirmed CR pts, 74% remain in CR at 2 yrs. EV302 via @tompowles1	Neutral	22

See full EV-302 conference coverage & trial data →

Trial 2 · NCT04700124

What do oncologists think of the KEYNOTE-B15 / EV-304 trial (PADCEV®)?

KEYNOTE-B15 / EV-304 — Perioperative (neoadjuvant + adjuvant) muscle-invasive bladder cancer undergoing radical cystectomy (EV + pembrolizumab)

FDA APPROVED · Jul 2026FDA-approved July 10, 2026, with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer — a label expansion to cisplatin-eligible patients (the November 2025 approval covered cisplatin-ineligible patients).

Physicians are broadly favorable, with real nuance on KEYNOTE-B15 / EV-304: 30% of 43 verified physician voices positive, 7% nuanced (praising the result while flagging a caveat), 63% neutral, 0% critical.

30%

63%

Positive 30% Nuanced 7% Neutral 63% Critical 0%

Denominator: 43 distinct verified physician voices across 126 oncologist posts, 2026-02-27 to 2026-07-11. Sponsor: Astellas Pharma and Merck

See full KEYNOTE-B15 / EV-304 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04700124 · FDA — perioperative MIBC approval (Jul 2026)

FDA approval (Jul 10, 2026): pembrolizumab (or pembrolizumab and berahyaluronidase alfa-pmph) each with enfortumab vedotin-ejfv as neoadjuvant, then adjuvant after cystectomy, for adults with muscle-invasive bladder cancer (based on EV-304 / KEYNOTE-B15, NCT04700124).

Physician voices — verbatim

Representative positive voice

KEYNOTE-B15/EV-304 trial is practice-changing: periop EV+ pem: 🔥 47% reduction in risk of events (HR 0.53) 🔥 Significant OS benefit (HR 0.65) 🔥 pCR 55.8% vs 32.5% A true paradigm shift for cisplatin-eligible MIBC. Honored to be part of this milestone with our HCSC team #GU26

Javier Puente

@docjavip

Representative nuanced voice

approved atezolizumab as adjuvant Tx in resected MIBC based on ctDNA #IMVigor011 (IO-naive patients). The candidate population is shrinking due to EV-303, EV-304, NIAGARA trials data but exists @BladderCancerUS @HsiehLab @spsutkaMD @OAlhalabiMD @shilpaonc @DrOmarMian

Petros Grivas

@PGrivasMDPhD

Full physician voice list (43)

Physician	Comment (verbatim)	Sentiment	Impressions
Andrea Apolo, M.D. @apolo_andrea	The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over…	Neutral	11,118
Tom Powles @tompowles1	3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting…	Neutral	9,863
Toni Choueiri, MD @DrChoueiri	Now, the combo of EV-Pembro is @US_FDA approved for all muscle-invasive bladder cancer @OncoAlert @AUC3_Official @Merck @BladderCancerUS @OncoBellmunt @bergsa83 @mouwlab https://t.co/jevkHqal0U	Neutral	7,001
Marta Orozco Belinchon @OrozcoBelinchon	Is this the end of cisplatin in MIBC? With the results from NIAGARA, KEYNOTE-B15/EV-304, and KEYNOTE-905/EV-303, along with the emergence of ctDNA in IMvigor011, it is becoming increasingly difficult to defend it as the sole backbone of pe…	Neutral	6,260
Axel S. Merseburger @amerseburger	Three studies: • PAnTHA • KEYNOTE-B15 • LITESPARK-022 from #ASCOGU2026 #GU26 that could potentially influence clinical practice in uro-oncology. #Medudy @DrChoueiri #Prostatecancer #Bladdercancer #renalcellcarcinoma #DigitalHealth @OncoA…	Neutral	4,973
Javier Puente @docjavip	KEYNOTE-B15/EV-304 trial is practice-changing: periop EV+ pem: 🔥 47% reduction in risk of events (HR 0.53) 🔥 Significant OS benefit (HR 0.65) 🔥 pCR 55.8% vs 32.5% A true paradigm shift for cisplatin-eligible MIBC. Honored to be part of this…	Positive	4,851
Sophia Kamran, MD @sophia_kamran	Day 2 (#bladder!) for @ASCO #GU26!! Really nice discussion by @DrTylerStewart of the KEYNOTE-B15 study ⭐️practice-changing, let's put discussion of ddMVAC to rest	Positive	3,002
David H Aggen, MD PhD @Dr_Aggen	UC Takeaways from #ASCOGU26 1) KEYNOTE-B15 is a landmark. Periop EV+pembro vs gem/cis in cis-eligible MIBC: EFS HR 0.53, pCR 55.8% vs 32.5%, OS benefit. First regimen to displace cisplatin in curative-intent bladder cancer in ~25 yrs.	Neutral	2,935
Dr Amol Akhade @SuyogCancer	Cross trial comparison and where we are heading in MIBC @asco #gu26 @DrChoueiri @dr_yakupergun @brunolarvol @OncoAlert @OncBrothers	Neutral	2,906
Oncology Brothers @OncBrothers	EV- Pembro is now @US_FDA ✅ Cis-ineligible off KEYNOTE-B15/EV-304: EV-Pembro (x4) —> Surg—> EV (x5) + Pembro (13) in resectable MIBC - 2yr EFS: 79.4% vs. 66.2% (HR: 0.53) - 2yr OS: 86.9% vs. 81.3% (HR: 0.65) - pCR: 55.8% vs. 32.5% - AEs: R…	Neutral	2,852
Dr Rishabh Jain @DrRishabhOnco	🚨 FDA has expanded perioperative pembrolizumab + enfortumab vedotin to all cystectomy-eligible patients with muscle-invasive bladder cancer, not just those ineligible for cisplatin. The approval is based on KEYNOTE-B15 / EV-304: 👥 808 p…	Neutral	2,366
Dra. María Natalia Gandur Quiroga @nataliagandur	🔷 KEYNOTE-B15 / EV-304 (LBA630) Presented by Matthew D. Galsky, MD #ASCOGU26 #GU26 #BladderCancer @OncoAlert Perioperative EV + pembrolizumab vs neoadjuvant cisplatin + gemcitabine in cisplatin-eligible MIBC: 🔹 EFS: HR 0.53 (95% CI 0.41–0.…	Neutral	2,217
Matt Campbell MD, MS @DocMattCampbell	What a start to bladder day at #GU26 @MattGalsky KEYNOTE B-15 first phase 3 to surpass cisplatin for NAC in MIBC. Now both trials with EVP in NAC space with consistently strong pCR, EFS, and OS allowing us to dream big about optimal bladde…	Positive	2,207
Dillon Cockrell, MD @DCockrellMD	Big day for #bladdercancer at #GU26 kicks off with much anticipated KNB15/EV304 trial for periop EV plus pembro vs neoadjuvant gem/cisplatin in MIBC. Significant improvements in both EFS and OS (HR 0.65) with pCR 55 vs 32% favoring EV-P. Ne…	Positive	2,052
Petros Grivas @PGrivasMDPhD	approved atezolizumab as adjuvant Tx in resected MIBC based on ctDNA #IMVigor011 (IO-naive patients). The candidate population is shrinking due to EV-303, EV-304, NIAGARA trials data but exists @BladderCancerUS @HsiehLab @spsutkaMD @OAlhala…	Nuanced	1,940
Enrique Grande @drenriquegrande	⚡️ Phase 3 KEYNOTE-B15/EV-304 at #ASCO26: perioperative EV + pembrolizumab vs gemcitabine/cisplatin in cisplatin-eligible MIBC. EFS HR 0.53. pCR 55.8% vs 32.5%. OS HR 0.65. First regimen in 25 years to surpass cisplatin-based neoadjuvant …	Neutral	1,808
Ashish M. Kamat, MD, MBBS @UroDocAsh	Great points. B15 establishes the potency of EVP but we have to be careful not to conflate maximum systemic efficacy with total local clearance - they’re not the same thing, and the 55.8% pCR rate, impressive as it is, didn’t eliminate the …	Nuanced	1,770
Alfonso Gómez de Liaño @Uro_Oncologist	Congrats @MattGalsky on a great presentation of KEYNOTE-B15. Impressive, practice-changing data. First platinum-free regimen to improve survival in cis-eligible MIBC (EFS HR 0.53; OS HR 0.65) with unprecedented pCR ~56%. These results supp…	Positive	1,688
Martín Angel @Martin_AngelMD	🆕 options for our patients!!! KEYNOTE-B15: Neo/adjuvant EV + pembro for participants with #MIBC cis-eligible study @MattGalsky @tompowles1 EFS: NR 🆚48.5 months (HR:0.53‼️) 2y estimated OS: 86.9 vs 81.3 %. (HR:0.65) @Blatam_urology @UroT…	Neutral	1,398
Maite Bourlon @BourlonMaite	DAY 2: #Urothelialcancer @asco #GU26 🟢 KEYNOTE-B15 EV + pembro cisplatin-eligible MIBC 📢 TOP abstract @MattGalsky 🧑‍🔬 RC48G001 P2 disitamab HER2+ previously tx aUC @tompowles1 🌅 SunRISe-2 Gem-intravesical +cetre vs ChemoRT in MIBC @A…	Neutral	1,381
Katy Beckermann @katy_beckermann	🔥 KEYNOTE-B15 is practice-changing and redefines perioperative management in cis-eligible MIBC. EV + pembrolizumab significantly improved: 📊 pCR: 55.8% vs 32.5% 📊 EFS: HR 0.53 📊 OS: HR 0.65 Yes, toxicity was higher (grade ≥3 AEs: 76% vs 6…	Positive	1,325
MV Chandrakanth @ChandrakanthMv	KEYNOTE-B15 / EV-304 #ASCO2026 Perioperative EV + Pembrolizumab vs Gemcitabine + Cisplatin in cisplatin-eligible MIBC: • 24-mo EFS: 79.4% vs 66.2% • HR for EFS: 0.53 • 24-mo OS: 86.9% vs 81.3% • pCR: 55.8% vs 32.5% Key message: Strong pe…	Neutral	1,298
Karine Tawagi MD @DrKarineTawagi	Groundbreaking KN-B15 for EVP in cis-eligible MIBC 👤 most T3/T4a, 90% pure urothelial 🎖️ EFS HR 0.53, OS HR 0.65, pCR 55.8% vs 32.5% ⚠️¾ grade 3 TEAE, 25% stopped NA EVP & 28.6% adj EVP d/t TEAE ‼️36% neuropathy, 63% skin, 23% 👁️ ❓h…	Neutral	1,128
Carlos Alvarez @duemed	Discussion on KEYNOTE-B15 by @DrTylerStewart at #GU26	Neutral	1,076
Zach Klaassen @zklaassen_md	⚡️UC Oral Abstract: Neoadj/adjuv EVP for cisplatin-eligible MIBC: Ph 3 KEYNOTE-B15 trial #GU26 @urotoday 📢Practice Changing Trial EVP vs Cis/Gem: 📍EFS: HR 0.53, 95% CI 0.41-0.70 📍OS: HR 0.65, 95% CI 0.48-0.89 📍pCR rate: 55.8% vs 32.5% 📍N…	Positive	1,067
Sara Coca Membribes @scocmem	#GU26 Starting 2nd day with impressive results of KN-B15 EVP in cis eligible patients improved EFS (79.4% vs 66.2%, HR 0.53), OS (86.9% vs 81.3%, HR 0.65) and pCR rate (55.8% vs 32.5%) This is the first time that a non-platinum regimen sh…	Positive	1,045
Max Kates @MaxKates	With EV-303 & EV-304 data, the challenge shifts to making up-front therapy the universal standard for MIBC. This #GU26 study suggests it won't happen overnight—real-world adoption often lags behind trial success. 🔗 Data:	Neutral	885
Mustafa Özdoğan, MD @ozdogan_md	20+ years in the making! #ASCOGU26 delivers a historic paradigm shift in Muscle-Invasive Bladder Cancer. KEYNOTE-B15 (LBA630) demonstrates that perioperative EV + Pembrolizumab unequivocally outperforms the platinum chemo standard in cispl…	Neutral	722
Markus Eckstein @Markuseckstein3	FDA approves neoadjuvant + adjuvant EV+pembro for muscle-invasive bladder cancer, now regardless of cisplatin eligibility. The first non-platinum regimen in ~25 years to beat cisplatin-based NAC head to head. EV-304 / KEYNOTE-B15 (n=808, E…	Neutral	721
Yüksel Ürün @DrYukselUrun	Practice changing in MIBC. @MattGalsky KEYNOTE-B15 / EV-304 shows perioperative enfortumab vedotin + pembrolizumab improved EFS and OS vs cis + gem in cisplatin-eligible patients. #gu26 #cancer #oncology @oncoalert @ASCO @medicalwatchBC …	Positive	611
Alireza Ghoreifi, MD @alirezaghoreifi	Check out @urotoday "Beyond the Abstract" commentary on our @UrolOncol paper, Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience 👉 https://t.co/6f0vKGlJI…	Neutral	605
Sabine D. Brookman-May @brookmans76	#GU26 Phase 3 KEYNOTE-B15 / EV-304: Neoadjuvant + adjuvant #enfortumab vedotin + #pembrolizumab vs cis/gem in cisplatin-eligible MIBC with impressive outcomes: ✅ EFS: HR 0.53 (p<0.0001) ✅ OS: HR 0.65 (p=0.0029) ✅ pCR: 55.8% vs 32.5% (+23.4%…	Positive	602
Jason Brown @jasonbrownmdphd	As we gear up for ASCO, I shared a summary of key urothelial cancer studies from GU ASCO a few months ago, including EV-304 and implications for the field in the future	Neutral	581
Michael Serzan, MD @MikeSerzanMD	🗣️Urothelial Oral Abstracts #GU26 👉Dr @MattGalsky presenting #KEYNOTEB15 comparing peri-operative #EVPembro vs gem/cis ⭐️EFS: NR vs 48.5mo (HR 0.53; 0.41-.070) ⭐️OS: NR vs NR (HR 0.65; 0.48-0.89) ⭐️pCR: 55.8 vs 32.…	Neutral	578
Shreyas Kalantri, MD @KalantriShreyas	EV-304 \| KEYNOTE-B15 Results #GU26 Perioperative EV + pembrolizumab significantly improved: • EFS: HR 0.53 (95% CI 0.41–0.70) 24-mo EFS 79.4% vs 66.2% • OS: HR 0.65 (0.48–0.89) 24-mo OS 86.9% vs 81.3% • pCR: 55.8% vs 32.5% (Δ 23.4%) Grade…	Neutral	567
Dr. Rodrigo Rivera 🩺 @Dr_RodrigoRiv	KN-B15/EV 304. Perioperative enfortumab vedotin + pembro is practice-change for cisplatin eligible and ineligible pf. Phase III trial shows: ✅ EFS: NR vs 48.5m HR 0.53 ✅ 2y OS: 86.9% vs 81.3% HR 0.65 ✅ pCR ~56% vs 32.5% Congrats for team @M…	Positive	514
DR CARVAJAL @romancarvajal	🚨 EV + Pembrolizumab is rapidly reshaping the perioperative bladder cancer landscape — and now raising real possibilities for bladder preservation in MIBC. KEYNOTE-905/EV-303 and KEYNOTE-B15/EV-304 demonstrated unprecedented improvements i…	Positive	476
Álvaro Pinto @dralvaropinto	Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. #GU26	Neutral	328
Mutlu Hizal @drmutluhizal	Well said! We definitely need the answer to this question—lots more to discuss. But first, let’s enjoy a couple of days of that 55% pCR ☺️	Nuanced	228
Yuhei YAMAGUCHI @yymgcmd	EV-304は術後Pembroのみかと思いきやEVも続くのね #GU26	Neutral	208
Prof. Dr. Ahmet Dirican @dr_dirican	POST 1/3 ASCO GU 2026: 10 Trials That May Redefine GU Oncology (1/3) This was not a meeting about incremental gains. It was about trajectory. Let’s start with bladder cancer. 1️⃣ KEYNOTE-B15 / EV-304 Perioperative Enfortumab Vedotin + P…	Neutral	202
MJosé Juan @mjuanfi81	#KEYNOTE-B15:Perioperative EV-pembrolizumab redefines the SOC (CisGem) in cisplatin-eligible MIBC: ✅EFS:HR 0.53 (P<0.0001) ✅OS:HR 0.65 (P=0.0029) 📣pCR:64.4% vs 36.3%(surgery) First phase 3 trial showing survival benefit with an ADC/IO in th…	Neutral	148
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD	Always a GUARANTEE: if Yousef Zakharia and I are in the building, we’re talking science… and than we end up laughing way too loud in the hallway. 😂 Massive congrats on being PI and one of the top enrollers on KEYNOTE-B15 — pushing EV + pe…	Positive	8

See full KEYNOTE-B15 / EV-304 conference coverage & trial data →

Regulatory

PADCEV® — FDA status

FDA APPROVEDPADCEV® (enfortumab vedotin-ejfv) is an FDA-approved Nectin-4-directed antibody-drug conjugate for urothelial cancer — first-line locally advanced or metastatic disease (with pembrolizumab), later-line metastatic disease as monotherapy, and, since July 2026, perioperative muscle-invasive bladder cancer (with pembrolizumab). For the full, current list of FDA indications and prescribing information, see padcev.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

PADCEV® sentiment — FAQ

EV-302

What do oncologists think of the EV-302 trial (PADCEV®)?

Across 27 verified physician voices in KOL Pulse's index for EV-302, 22% expressed positive sentiment, 11% were nuanced (praising the result while flagging a caveat), 67% were neutral, and 0% were critical. Positive voices highlight the first regimen to beat platinum-based chemotherapy in advanced urothelial cancer, establishing enfortumab vedotin + pembrolizumab as the new first-line standard of care; nuanced and critical voices flag cumulative toxicity of the ADC + immunotherapy backbone (including skin and neuropathy) and patient selection/sequencing in real-world practice.

Where can I find the EV-302 trial data for PADCEV® (enfortumab vedotin)?

EV-302 is registered as NCT04223856 and studied PADCEV® (enfortumab vedotin) in 1L locally advanced or metastatic urothelial cancer (EV + pembrolizumab). For the full EV-302 trial data and conference coverage, see the KOL Pulse EV-302 trial profile at kolpulse.com/kol-pulse-trial-profile-ev302.

KEYNOTE-B15 / EV-304

What do oncologists think of the KEYNOTE-B15 / EV-304 trial (PADCEV®)?

Across 43 verified physician voices in KOL Pulse's index for KEYNOTE-B15 / EV-304, 30% expressed positive sentiment, 7% were nuanced (praising the result while flagging a caveat), 63% were neutral, and 0% were critical. Positive voices highlight the first platinum-free perioperative regimen to improve outcomes over standard chemotherapy in muscle-invasive bladder cancer, moving enfortumab vedotin + pembrolizumab into curative-intent therapy; nuanced and critical voices flag a shrinking candidate population versus competing approaches (e.g. ctDNA-guided adjuvant immunotherapy), perioperative toxicity, and overall-survival maturity.

Where can I find the KEYNOTE-B15 / EV-304 trial data for PADCEV® (enfortumab vedotin)?

KEYNOTE-B15 / EV-304 is registered as NCT04700124 and studied PADCEV® (enfortumab vedotin) in Perioperative (neoadjuvant + adjuvant) muscle-invasive bladder cancer undergoing radical cystectomy (EV + pembrolizumab). For the full KEYNOTE-B15 / EV-304 trial data and conference coverage, see the KOL Pulse KEYNOTE-B15 / EV-304 trial profile at kolpulse.com/kol-pulse-trial-profile-keynote-b15.

Regulatory

Is PADCEV® (enfortumab vedotin) FDA approved?

PADCEV® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.